Global API Intermediate Market Size, Share & Industry Trends Analysis Report By Type (Bulk Drug Intermediates, and Chemical Intermediates), By End User (Biotech & Pharmaceutical Companies, CMO), By Application, By Regional Outlook and Forecast, 2023 - 20

Global API Intermediate Market Size, Share & Industry Trends Analysis Report By Type (Bulk Drug Intermediates, and Chemical Intermediates), By End User (Biotech & Pharmaceutical Companies, CMO), By Application, By Regional Outlook and Forecast, 2023 - 2030


The Global API Intermediate Market size is expected to reach $237.7 billion by 2030, rising at a market growth of 7.2% CAGR during the forecast period.

The Asia-Pacific region has a significant concentration of producers of API intermediates, and chronic disease incidence has increased. Consequently, Asia-Pacific region is anticipated to capture more than 35% share of the market by 2030. The pharmaceutical and contract manufacturing industries are expanding in several nations, including China and India, which is projected to boost the Asia Pacific region. Due to considerations like cheaper labor costs and the accessibility of production-ready raw materials, these nations have emerged as desirable locations for outsourcing the manufacturing of active ingredients. The expansion of manufacturing capacity in the region is also encouraged by favorable regulatory policies in Asia Pacific, fostering the market’s development. Some of the factors impacting the market are strong demand for pharmaceuticals, increasing incidence of chronic illness, and biopharmaceutical drugs are expensive.

The prevalence of chronic diseases is rising rapidly around the world due to the aging of the population, the rise of sedentary lifestyles, and urbanization. As a result, there is an ever-growing market demand for therapeutic drugs. Additionally, several pharmaceutical firms’ introduction of novel pharmaceuticals to the market is projected to increase the focus on research and development operations, which would likely fuel the expansion of the market throughout the projection period. The rise in healthcare expenditures per capita in developing nations, coupled with the increase in diagnosis rates, has resulted in a large population requiring treatment. This rising prevalence of chronic diseases is also expected to increase demand for pharmaceuticals in the market for active pharmaceutical ingredients. Increasing pharmaceutical demand will drive the demand for branded and generic products. As a result of the rising incidence of chronic illness, the market is estimated to grow.

However, Research and development funding for novel drugs and APIs may be reduced due to pharmaceuticals. The pipeline of novel drugs and, consequently, their API intermediates could be limited, which could slow innovation. Due to the high cost of biological medications, market dynamics may shift, leading to more stringent restrictions and cost-cutting initiatives. These modifications may affect the pharmaceutical and, consequently, the market. This factor poses a challenge for the market. The market suffered greatly due to the COVID-19 outbreak. The lack of raw materials required for the production of API intermediates and the stringent government regulations governing the supply chain resulted in negatively impacting the market.

Type Outlook

By type, the market is classified into bulk drug intermediates and chemical intermediates. In 2022, the bulk drug intermediates segment held the highest revenue share in the market. Due to the rising frequency of chronic diseases and the growth in market participants who produce bulk drug intermediates, the bulk drug intermediates sector is anticipated to dominate the market. Active pharmaceutical ingredients (API) are frequently produced using bulk drug intermediates. The active pharmaceutical ingredient (API) is the essential component used in the production of medications to have the desired therapeutic effect.

End User Outlook

On the basis of end user, the market is segmented into biotech & pharmaceutical companies, CMO, and others. The CMOs segment recorded a remarkable revenue share in the market in 2022. CMOs frequently concentrate on particular therapeutic areas or specialize in the manufacturing of particular types of API intermediates. Their knowledge enables them to enhance manufacturing procedures, boost productivity, and guarantee high-quality output, attracting clients looking for dependable and effective API intermediates. Hence, their demand will increase the market segment further.

Application Outlook

Based on application, the market is bifurcated into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs, and others. In 2022, the cardiovascular drugs segment acquired a substantial revenue share in the market. Due to its healing qualities, API Intermediate is widely utilized in cardiovascular diseases. One of the main causes of death globally is cardiovascular disease. Throughout the projected period, there is anticipated to be a noticeable increase in the usage of API Intermediate in the treatment of cardiovascular disorders.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. The rise in senior populations is projected to contribute to the market in North America expanding at a noticeable rate over the forecast period. The aging population is more prone to chronic illnesses like cardiac, orthopedic, respiratory, and other diseases. Thus, an increase in the geriatric population increases the demand for pharmaceuticals and API intermediates, thereby driving market expansion. As a result, the growth of this market in the North American region has been fuelled by the rise in the incidence of these chronic illnesses.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Cation Pharma, Espee Group, Sandoo Pharmaceuticals and Chemicals Co., Ltd., Cipla Limited, Cambrex Corporation, Vertellus, Dr. Reddy’s Laboratories Ltd., Evonik Industries AG (RAG-Stiftung), Pfizer, Inc., Shree Ganesh Remedies Limited

Strategies Deployed in API Intermediate Market

Jul-2023: Evonik Industries AG partnered with Heraeus Precious Metals, a precious metal products provider, to expand its highly potent active pharmaceutical ingredients (HPAPIs) service portfolio. The partnership would enhance Evonik's HPAPI capabilities.

May-2023: Evonik Industries AG signed a distribution partnership with IMCD, a specialty chemicals distributor, to market Evonik's medicines in the European market. The partnership provides Evonik with an opportunity to accelerate its business growth.

Mar-2023: Evonik Industries AG expanded its geographical footprint by opening a new facility in Hanau, Germany. The new facility would serve as a lipid manufacturing hub. The lipids produced at the facility would be used in the company's RNA drugs.

Feb-2023: Dr. Reddy’s Laboratories Ltd. entered a distribution partnership with Aster Pharmacy, a pharmacy chain based in the GCC, to market its medicines in the Gulf region. The partnership enables Dr. Reddy’s Laboratories to expand its customer base.

Nov-2022: Cambrex Corporation announced the acquisition of Snapdragon Chemistry, a chemical process development service provider. The acquisition enhances Cambrex's capabilities in continuous flow process manufacturing and development.

Oct-2022: Evonik Industries AG came into partnership with Phathom Pharmaceuticals, a biopharmaceutical company based in the US, to manufacture the gastrointestinal disorder treatment drug vonoprazan. The partnership comes in line with Evonik's commitment to deliver complex APIs for customers around the globe.

May-2022: Pfizer Inc. established a drug development center in Chennai, India. The center would be used for the development of active pharmaceutical ingredients (APIs) and would aid the company's global manufacturing operations.

Feb-2019: Aavis Pharmaceuticals, a subsidiary of Espee Group, received approval from the US Food and Drug Administration for its manufacturing plant in the United States. The approval places Espee as the 3rd company in Gujarat to have a US-based plant approved by the USFDA.

Jan-2019: Cambrex Corporation acquired Avista Pharma Solutions, a CDMO based in the US. The acquisition strengthens Cambrex's capabilities in APIs by adding Avista’s early-stage development to Cambrex's portfolio.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Bulk Drug Intermediates
  • Chemical Intermediates
By End User
  • Biotech & Pharmaceutical Companies
  • CMO
  • Others
By Application
  • Analgesics
  • Antidiabetic Drugs
  • Anti-Infective Drugs
  • Cardiovascular Drugs
  • Anticancer Drugs
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Cation Pharma
  • Espee Group
  • Sandoo Pharmaceuticals and Chemicals Co., Ltd.
  • Cipla Limited
  • Cambrex Corporation
  • Vertellus
  • Dr. Reddy’s Laboratories Ltd.
  • Evonik Industries AG (RAG-Stiftung)
  • Pfizer, Inc.
  • Shree Ganesh Remedies Limited
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global API Intermediate Market, by Type
1.4.2 Global API Intermediate Market, by End User
1.4.3 Global API Intermediate Market, by Application
1.4.4 Global API Intermediate Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies Deployed in API Intermediate Market
Chapter 5. Global API Intermediate Market by Type
5.1 Global Bulk Drug Intermediates Market by Region
5.2 Global Chemical Intermediates Market by Region
Chapter 6. Global API Intermediate Market by End User
6.1 Global Biotech & Pharmaceutical Companies Market by Region
6.2 Global CMO Market by Region
6.3 Global Others Market by Region
Chapter 7. Global API Intermediate Market by Application
7.1 Global Analgesics Market by Region
7.2 Global Antidiabetic Drugs Market by Region
7.3 Global Anti-Infective Drugs Market by Region
7.4 Global Cardiovascular Drugs Market by Region
7.5 Global Anticancer Drugs Market by Region
7.6 Global Others Market by Region
Chapter 8. Global API Intermediate Market by Region
8.1 North America API Intermediate Market
8.1.1 North America API Intermediate Market by Type
8.1.1.1 North America Bulk Drug Intermediates Market by Country
8.1.1.2 North America Chemical Intermediates Market by Country
8.1.2 North America API Intermediate Market by End User
8.1.2.1 North America Biotech & Pharmaceutical Companies Market by Country
8.1.2.2 North America CMO Market by Country
8.1.2.3 North America Others Market by Country
8.1.3 North America API Intermediate Market by Application
8.1.3.1 North America Analgesics Market by Country
8.1.3.2 North America Antidiabetic Drugs Market by Country
8.1.3.3 North America Anti-Infective Drugs Market by Country
8.1.3.4 North America Cardiovascular Drugs Market by Country
8.1.3.5 North America Anticancer Drugs Market by Country
8.1.3.6 North America Others Market by Country
8.1.4 North America API Intermediate Market by Country
8.1.4.1 US API Intermediate Market
8.1.4.1.1 US API Intermediate Market by Type
8.1.4.1.2 US API Intermediate Market by End User
8.1.4.1.3 US API Intermediate Market by Application
8.1.4.2 Canada API Intermediate Market
8.1.4.2.1 Canada API Intermediate Market by Type
8.1.4.2.2 Canada API Intermediate Market by End User
8.1.4.2.3 Canada API Intermediate Market by Application
8.1.4.3 Mexico API Intermediate Market
8.1.4.3.1 Mexico API Intermediate Market by Type
8.1.4.3.2 Mexico API Intermediate Market by End User
8.1.4.3.3 Mexico API Intermediate Market by Application
8.1.4.4 Rest of North America API Intermediate Market
8.1.4.4.1 Rest of North America API Intermediate Market by Type
8.1.4.4.2 Rest of North America API Intermediate Market by End User
8.1.4.4.3 Rest of North America API Intermediate Market by Application
8.2 Europe API Intermediate Market
8.2.1 Europe API Intermediate Market by Type
8.2.1.1 Europe Bulk Drug Intermediates Market by Country
8.2.1.2 Europe Chemical Intermediates Market by Country
8.2.2 Europe API Intermediate Market by End User
8.2.2.1 Europe Biotech & Pharmaceutical Companies Market by Country
8.2.2.2 Europe CMO Market by Country
8.2.2.3 Europe Others Market by Country
8.2.3 Europe API Intermediate Market by Application
8.2.3.1 Europe Analgesics Market by Country
8.2.3.2 Europe Antidiabetic Drugs Market by Country
8.2.3.3 Europe Anti-Infective Drugs Market by Country
8.2.3.4 Europe Cardiovascular Drugs Market by Country
8.2.3.5 Europe Anticancer Drugs Market by Country
8.2.3.6 Europe Others Market by Country
8.2.4 Europe API Intermediate Market by Country
8.2.4.1 Germany API Intermediate Market
8.2.4.1.1 Germany API Intermediate Market by Type
8.2.4.1.2 Germany API Intermediate Market by End User
8.2.4.1.3 Germany API Intermediate Market by Application
8.2.4.2 UK API Intermediate Market
8.2.4.2.1 UK API Intermediate Market by Type
8.2.4.2.2 UK API Intermediate Market by End User
8.2.4.2.3 UK API Intermediate Market by Application
8.2.4.3 France API Intermediate Market
8.2.4.3.1 France API Intermediate Market by Type
8.2.4.3.2 France API Intermediate Market by End User
8.2.4.3.3 France API Intermediate Market by Application
8.2.4.4 Russia API Intermediate Market
8.2.4.4.1 Russia API Intermediate Market by Type
8.2.4.4.2 Russia API Intermediate Market by End User
8.2.4.4.3 Russia API Intermediate Market by Application
8.2.4.5 Spain API Intermediate Market
8.2.4.5.1 Spain API Intermediate Market by Type
8.2.4.5.2 Spain API Intermediate Market by End User
8.2.4.5.3 Spain API Intermediate Market by Application
8.2.4.6 Italy API Intermediate Market
8.2.4.6.1 Italy API Intermediate Market by Type
8.2.4.6.2 Italy API Intermediate Market by End User
8.2.4.6.3 Italy API Intermediate Market by Application
8.2.4.7 Rest of Europe API Intermediate Market
8.2.4.7.1 Rest of Europe API Intermediate Market by Type
8.2.4.7.2 Rest of Europe API Intermediate Market by End User
8.2.4.7.3 Rest of Europe API Intermediate Market by Application
8.3 Asia Pacific API Intermediate Market
8.3.1 Asia Pacific API Intermediate Market by Type
8.3.1.1 Asia Pacific Bulk Drug Intermediates Market by Country
8.3.1.2 Asia Pacific Chemical Intermediates Market by Country
8.3.2 Asia Pacific API Intermediate Market by End User
8.3.2.1 Asia Pacific Biotech & Pharmaceutical Companies Market by Country
8.3.2.2 Asia Pacific CMO Market by Country
8.3.2.3 Asia Pacific Others Market by Country
8.3.3 Asia Pacific API Intermediate Market by Application
8.3.3.1 Asia Pacific Analgesics Market by Country
8.3.3.2 Asia Pacific Antidiabetic Drugs Market by Country
8.3.3.3 Asia Pacific Anti-Infective Drugs Market by Country
8.3.3.4 Asia Pacific Cardiovascular Drugs Market by Country
8.3.3.5 Asia Pacific Anticancer Drugs Market by Country
8.3.3.6 Asia Pacific Others Market by Country
8.3.4 Asia Pacific API Intermediate Market by Country
8.3.4.1 China API Intermediate Market
8.3.4.1.1 China API Intermediate Market by Type
8.3.4.1.2 China API Intermediate Market by End User
8.3.4.1.3 China API Intermediate Market by Application
8.3.4.2 Japan API Intermediate Market
8.3.4.2.1 Japan API Intermediate Market by Type
8.3.4.2.2 Japan API Intermediate Market by End User
8.3.4.2.3 Japan API Intermediate Market by Application
8.3.4.3 India API Intermediate Market
8.3.4.3.1 India API Intermediate Market by Type
8.3.4.3.2 India API Intermediate Market by End User
8.3.4.3.3 India API Intermediate Market by Application
8.3.4.4 South Korea API Intermediate Market
8.3.4.4.1 South Korea API Intermediate Market by Type
8.3.4.4.2 South Korea API Intermediate Market by End User
8.3.4.4.3 South Korea API Intermediate Market by Application
8.3.4.5 Singapore API Intermediate Market
8.3.4.5.1 Singapore API Intermediate Market by Type
8.3.4.5.2 Singapore API Intermediate Market by End User
8.3.4.5.3 Singapore API Intermediate Market by Application
8.3.4.6 Malaysia API Intermediate Market
8.3.4.6.1 Malaysia API Intermediate Market by Type
8.3.4.6.2 Malaysia API Intermediate Market by End User
8.3.4.6.3 Malaysia API Intermediate Market by Application
8.3.4.7 Rest of Asia Pacific API Intermediate Market
8.3.4.7.1 Rest of Asia Pacific API Intermediate Market by Type
8.3.4.7.2 Rest of Asia Pacific API Intermediate Market by End User
8.3.4.7.3 Rest of Asia Pacific API Intermediate Market by Application
8.4 LAMEA API Intermediate Market
8.4.1 LAMEA API Intermediate Market by Type
8.4.1.1 LAMEA Bulk Drug Intermediates Market by Country
8.4.1.2 LAMEA Chemical Intermediates Market by Country
8.4.2 LAMEA API Intermediate Market by End User
8.4.2.1 LAMEA Biotech & Pharmaceutical Companies Market by Country
8.4.2.2 LAMEA CMO Market by Country
8.4.2.3 LAMEA Others Market by Country
8.4.3 LAMEA API Intermediate Market by Application
8.4.3.1 LAMEA Analgesics Market by Country
8.4.3.2 LAMEA Antidiabetic Drugs Market by Country
8.4.3.3 LAMEA Anti-Infective Drugs Market by Country
8.4.3.4 LAMEA Cardiovascular Drugs Market by Country
8.4.3.5 LAMEA Anticancer Drugs Market by Country
8.4.3.6 LAMEA Others Market by Country
8.4.4 LAMEA API Intermediate Market by Country
8.4.4.1 Brazil API Intermediate Market
8.4.4.1.1 Brazil API Intermediate Market by Type
8.4.4.1.2 Brazil API Intermediate Market by End User
8.4.4.1.3 Brazil API Intermediate Market by Application
8.4.4.2 Argentina API Intermediate Market
8.4.4.2.1 Argentina API Intermediate Market by Type
8.4.4.2.2 Argentina API Intermediate Market by End User
8.4.4.2.3 Argentina API Intermediate Market by Application
8.4.4.3 UAE API Intermediate Market
8.4.4.3.1 UAE API Intermediate Market by Type
8.4.4.3.2 UAE API Intermediate Market by End User
8.4.4.3.3 UAE API Intermediate Market by Application
8.4.4.4 Saudi Arabia API Intermediate Market
8.4.4.4.1 Saudi Arabia API Intermediate Market by Type
8.4.4.4.2 Saudi Arabia API Intermediate Market by End User
8.4.4.4.3 Saudi Arabia API Intermediate Market by Application
8.4.4.5 South Africa API Intermediate Market
8.4.4.5.1 South Africa API Intermediate Market by Type
8.4.4.5.2 South Africa API Intermediate Market by End User
8.4.4.5.3 South Africa API Intermediate Market by Application
8.4.4.6 Nigeria API Intermediate Market
8.4.4.6.1 Nigeria API Intermediate Market by Type
8.4.4.6.2 Nigeria API Intermediate Market by End User
8.4.4.6.3 Nigeria API Intermediate Market by Application
8.4.4.7 Rest of LAMEA API Intermediate Market
8.4.4.7.1 Rest of LAMEA API Intermediate Market by Type
8.4.4.7.2 Rest of LAMEA API Intermediate Market by End User
8.4.4.7.3 Rest of LAMEA API Intermediate Market by Application
Chapter 9. Company Profiles
9.1 Cation Pharma
9.1.1 Company Overview
9.1.2 SWOT Analysis
9.2 Espee Group
9.2.1 Company Overview
9.2.2 Recent strategies and developments:
9.2.2.1 Trials and Approvals:
9.3 Sandoo Pharmaceuticals and Chemicals Co., Ltd.
9.3.1 Company Overview
9.3.2 SWOT Analysis
9.4 Cipla Limited
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Cambrex Corporation
9.5.1 Company Overview
9.5.2 Recent strategies and developments:
9.5.2.1 Acquisition and Mergers:
9.5.3 SWOT Analysis
9.6 Vertellus
9.6.1 Company Overview
9.6.2 SWOT Analysis
9.7 Dr. Reddy’s Laboratories Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.6 SWOT Analysis
9.8 Evonik Industries AG (RAG-Stiftung)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Geographical Expansions:
9.8.6 SWOT Analysis
9.9 Pfizer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional & Segmental Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Geographical Expansions:
9.9.6 SWOT Analysis
9.10. SHREE GANESH REMEDIES LIMITED
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 SWOT Analysis
Chapter 10. Winning Imperative for API Intermediate Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings